JP2022551316A5 - - Google Patents

Info

Publication number
JP2022551316A5
JP2022551316A5 JP2022521569A JP2022521569A JP2022551316A5 JP 2022551316 A5 JP2022551316 A5 JP 2022551316A5 JP 2022521569 A JP2022521569 A JP 2022521569A JP 2022521569 A JP2022521569 A JP 2022521569A JP 2022551316 A5 JP2022551316 A5 JP 2022551316A5
Authority
JP
Japan
Prior art keywords
theta
powder
ray diffraction
crystal form
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/078493 external-priority patent/WO2021069711A1/en
Publication of JP2022551316A publication Critical patent/JP2022551316A/ja
Publication of JP2022551316A5 publication Critical patent/JP2022551316A5/ja
Pending legal-status Critical Current

Links

JP2022521569A 2019-10-10 2020-10-09 Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 Pending JP2022551316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913560P 2019-10-10 2019-10-10
US62/913,560 2019-10-10
PCT/EP2020/078493 WO2021069711A1 (en) 2019-10-10 2020-10-09 Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea

Publications (2)

Publication Number Publication Date
JP2022551316A JP2022551316A (ja) 2022-12-08
JP2022551316A5 true JP2022551316A5 (enExample) 2023-10-17

Family

ID=72852650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521569A Pending JP2022551316A (ja) 2019-10-10 2020-10-09 Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形

Country Status (5)

Country Link
US (2) US12338249B2 (enExample)
EP (1) EP4041739A1 (enExample)
JP (1) JP2022551316A (enExample)
CN (1) CN115279769A (enExample)
WO (1) WO2021069711A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (enExample) 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
JP2859791B2 (ja) 1992-01-31 1999-02-24 吉富製薬株式会社 ４−ブロモメチルビフェニル化合物の製造法
JPH10298156A (ja) 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd 置換ハロメチルフェニルカルバミド酸エステル類の製造方法
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
JP2001316391A (ja) 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
US6849738B2 (en) 2000-02-29 2005-02-01 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
GB2361917A (en) 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002088044A (ja) 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd ４’−ブロモメチル−２−シアノビフェニルの製造方法
DE60207280T2 (de) 2001-09-04 2006-05-18 Akzo Nobel N.V. GLYCINSUBSTITUIERTE THIENO[2,3-d]PYRIMIDINE MIT KOMBINIERTER LH- UND FSH-AGONISTISCHER WIRKUNG
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
WO2006014647A2 (en) 2004-07-21 2006-02-09 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
EP1806053A1 (en) 2004-10-25 2007-07-11 Nihon Nohyaku Co., Ltd. Herbicide compositions for upland farming and control method
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
US20110172249A1 (en) 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
JP2010229098A (ja) * 2009-03-27 2010-10-14 Central Glass Co Ltd イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形
TWI508962B (zh) 2009-04-22 2015-11-21 Du Pont 氮雜環醯胺之固體形態
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
TWI744224B (zh) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
JP2017088564A (ja) * 2015-11-13 2017-05-25 株式会社トクヤマ ミルタザピンの製造方法
CN108430990B (zh) * 2015-12-25 2020-08-25 山东轩竹医药科技有限公司 喹唑啉衍生物的晶体及其制备方法
TWI726969B (zh) * 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US20170275330A1 (en) 2016-03-28 2017-09-28 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
EP3969455A4 (en) * 2019-05-15 2023-07-05 Dr. Reddy's Laboratories Limited AMORPHOUS AND CRYSTALLINE FORMS OF RELUGOLIX
CA3145993A1 (en) * 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
CN112390812A (zh) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
CN112771052B (zh) 2019-08-21 2023-04-07 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN112552312B (zh) 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN113620972A (zh) 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
WO2023042214A1 (en) 2021-09-15 2023-03-23 Cipla Limited Solid state forms of relugolix
CN115947734A (zh) 2021-10-09 2023-04-11 江苏希迪制药有限公司 瑞卢戈利溶剂化物的晶型及其制备方法
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023119333A1 (en) 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
IN202221021078A (enExample) 2022-04-08 2023-10-13
CN115417883B (zh) 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法

Similar Documents

Publication Publication Date Title
JP2022551525A5 (enExample)
JP2024540922A5 (enExample)
JP2025176008A5 (enExample)
JP2023522040A5 (enExample)
CA2727680A1 (en) 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
JP2023548859A5 (enExample)
JP4193949B2 (ja) Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド
US6352981B1 (en) Substituted AZA- and diazacycloheptane and -cyclooctane
TW555735B (en) Diarylpropylamines, methods for their preparation and pharmaceutical compositions containing them
JP2024505063A5 (enExample)
US20030186981A1 (en) Benzamide, heteroarylamide and reverse amides
JP2020059759A5 (enExample)
NZ573698A (en) Barbituric and thiobarbituric amino acid derivatives as prolyl hydroxylase inhibitors
JP2018527336A5 (enExample)
CA2537092A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TW200800182A (en) Nitrogen-containing heterocyclic derivatives substituted by ring-type groups
JP2009539762A (ja) Ｈ３受容体のテトラリン拮抗薬
CN101115482A (zh) 杂环天冬氨酰蛋白酶抑制剂
CA2594345A1 (en) Compositions and methods of treating cell proliferation disorders
TW200838511A (en) Novel pharmaceutical compounds
US20060089371A1 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
EP1532138A1 (en) Inhibitors of tyrosine kinases
JPWO2005095382A1 (ja) 抗腫瘍剤
JP2024103495A5 (enExample)
US20160229834A1 (en) Quinazoline derivatives and their use as dna methyltransferase inhibitors